Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Abstract C057: A phase I study to access the safety and efficacy of valecobulin (CKD-516), oral vascular disruption agent, in combination with irinotecan in patients with previously treated metastatic colorectal cancer

Tae Won Kim, Jeong Eun Kim, Hyeong-Seok Lim, Young Suk Park, Won Ki Kang, Sang Joon Shin, Joong Bae Ahn, Sae-Won Han, Tae-You Kim

Mol Cancer Ther (2019) 18 (12_Supplement): C057.

https://doi.org/10.1158/1535-7163.TARG-19-C057

Published: 01 December 2019

View article titled, Abstract C057: A phase I study to access the safety and efficacy of valecobulin (CKD-516), oral vascular disruption agent, in combination with irinotecan in patients with previously treated metastatic colorectal cancer

Journal Articles

Abstract B100: Mutant KRAS-induced macrophage migration inhibitory factor (MIF) secretion promotes resistance to cetuximab in colorectal cancer

Jee Eun Jang, Hwang-Phill Kim, Sae Won Han, Tae You Kim

Mol Cancer Ther (2018) 17 (1_Supplement): B100.

https://doi.org/10.1158/1535-7163.TARG-17-B100

Published: 01 January 2018

View article titled, Abstract B100: Mutant KRAS-induced macrophage migration inhibitory factor (MIF) secretion promotes resistance to cetuximab in colorectal cancer

Journal Articles

Src as a Therapeutic Target in Biliary Tract Cancer

Ah-Rong Nam, Ji-Won Kim, Ji Eun Park, Ju-Hee Bang, Mei Hua Jin, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang

Mol Cancer Ther (2016) 15 (7): 1515–1524.

https://doi.org/10.1158/1535-7163.MCT-16-0013

Published: 05 July 2016

View article titled, Src as a Therapeutic Target in Biliary Tract Cancer

Includes: Supplementary data

Journal Articles

Abstract A72: Mutation signature associated with colorectal cancer prognosis identified by targeted next-generation sequencing

Dae-Won Lee, Yongjun Cha, Sae-Won Han, Si-Hyun Lee, Hwang-Phill Kim, Jaemyun Lyu, Hyojun Han, Hyoki Kim, Hoon Jang, Duhee Bang, Iksoo Huh, Taesung Park, Jeong Mo Bae, Jae-Kyung Won, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Tae-You Kim

Mol Cancer Ther (2015) 14 (12_Supplement_2): A72.

https://doi.org/10.1158/1535-7163.TARG-15-A72

Published: 01 December 2015

View article titled, Abstract A72: Mutation signature associated with colorectal cancer prognosis identified by targeted next-generation sequencing

Journal Articles

Abstract A2: Clinical implications of anti-angiogenic effect of regorafenib in metastatic colorectal cancer

Yoojoo Lim, Sae-Won Han, Jeong Hee Yoon, Jeong Min Lee, Jung Min Lee, Jin Chul Paeng, Jae-Kyung Won, Gyeong Hoon Kang, Seung-Yong Jeong, Kyu Joo Park, Kyung-Hun Lee, Jee Hyun Kim, Tae-You Kim

Mol Cancer Ther (2015) 14 (12_Supplement_2): A2.

https://doi.org/10.1158/1535-7163.TARG-15-A2

Published: 01 December 2015

View article titled, Abstract A2: Clinical implications of anti-angiogenic effect of regorafenib in metastatic colorectal cancer

Journal Articles

Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.

Do-Youn Oh, Ah-Rong Nam, Tae Yong Kim, Sae-Won Han, Sang-Hyun Song, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang

Mol Cancer Ther (2013) 12 (11_Supplement): C266.

https://doi.org/10.1158/1535-7163.TARG-13-C266

Published: 01 November 2013

View article titled, Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.

Journal Articles

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, Yung-Jue Bang

Mol Cancer Ther (2013) 12 (6): 865–877.

https://doi.org/10.1158/1535-7163.MCT-12-0950

Published: 09 June 2013

View article titled, RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Includes: Supplementary data

Journal Articles

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Hyun-Jin Nam, Seock-Ah Im, Do-Youn Oh, Paul Elvin, Hwang-Phill Kim, Young-Kwang Yoon, Ahrum Min, Sang-Hyun Song, Sae-Won Han, Tae-You Kim, Yung-Jue Bang

Mol Cancer Ther (2013) 12 (1): 16–26.

https://doi.org/10.1158/1535-7163.MCT-12-0109

Published: 13 January 2013

View article titled, Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Includes: Supplementary data

Journal Articles

Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Hyun-Jin Nam, Keith A. Ching, Julie Kan, Hwang-Phill Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, James G. Christensen, Do-Youn Oh, Yung-Jue Bang

Mol Cancer Ther (2012) 11 (2): 439–451.

https://doi.org/10.1158/1535-7163.MCT-11-0494

Published: 08 February 2012

View article titled, Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Includes: Supplementary data

Journal Articles

Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Hyun‐Jin Nam, Hwang‐Phill Kim, Young‐Kwang Yoon, Hyung‐Seok Hur, Maeng‐Sup Kim, Gwan‐Sun Lee, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang

Mol Cancer Ther (2009) 8 (12_Supplement): B260.

https://doi.org/10.1158/1535-7163.TARG-09-B260

Published: 10 December 2009

View article titled, Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Journal Articles

Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach

Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han, Seock‐Ah Im, Do Youn Oh, Yung‐Jue Bang, Tae‐You Kim

Mol Cancer Ther (2009) 8 (12_Supplement): A252.

https://doi.org/10.1158/1535-7163.TARG-09-A252

Published: 10 December 2009

View article titled, Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach

Journal Articles

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Young-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, Hyung-Seok Hur, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim

Mol Cancer Ther (2009) 8 (9): 2526–2536.

https://doi.org/10.1158/1535-7163.MCT-09-0300

Published: 17 September 2009

View article titled, Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Includes: Supplementary data

Journal Articles

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Hwang-Phill Kim, Sae-Won Han, Sung-Hak Kim, Seock-Ah Im, Do-Youn Oh, Yung-Jue Bang, Tae-You Kim

Mol Cancer Ther (2008) 7 (3): 607–615.

https://doi.org/10.1158/1535-7163.MCT-07-2068

Published: 17 March 2008

View article titled, Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

NARROW

Abstract C057: A phase I study to access the safety and efficacy of valecobulin (CKD-516), oral vascular disruption agent, in combination with irinotecan in patients with previously treated metastatic colorectal cancer

Abstract B100: Mutant KRAS-induced macrophage migration inhibitory factor (MIF) secretion promotes resistance to cetuximab in colorectal cancer

Src as a Therapeutic Target in Biliary Tract Cancer

Abstract A72: Mutation signature associated with colorectal cancer prognosis identified by targeted next-generation sequencing

Abstract A2: Clinical implications of anti-angiogenic effect of regorafenib in metastatic colorectal cancer

Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only